DIA Biosimilars Virtual Conference
DIA Global presented “Biosimilars Virtual Conference Session 1: Barriers to Uptake of Biosimilars in the U.S.” on August 22, 2018. The conference addressed the evolution of biosimilar landscape in regard to uptake challenges in the US.
Featured topics included:
1. Lack of Understanding: Perception Challenges and Misinformation
-
Effectiveness and safety of biosimilars
-
Extrapolation
-
Quality of biosimilars vs interchangeable biologics
-
Physician-initiated switching and pharmacists-initiated switching (substitution and interchangeability)
2. Commercial Challenges
-
Effectiveness and safety of biosimilars
-
Extrapolation
-
Quality of biosimilars vs interchangeable biologics
-
Physician-initiated switching and pharmacists-initiated switching (substitution and interchangeability)
3. Legal Challenges
-
Effectiveness and safety of biosimilars
-
Extrapolation
-
Quality of biosimilars vs interchangeable biologics
-
Physician-initiated switching and pharmacists-initiated switching (substitution and interchangeability)
Partner Amanda Hollis spoke on the panel. Amanda was joined by Hillel Cohen of Sandoz, Inc., Jenny Alltoft of Pfizer Essential Health and Javier Coindreau of Pfizer, Inc.
